Clinical trial analysis of 2019‐nCoV therapy registered in China

Q Zhang, Y Wang, C Qi, L Shen… - Journal of medical …, 2020 - Wiley Online Library
So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and
more patients diagnosed, China has carried out more than 100 clinical studies of new …

[HTML][HTML] Claudin18. 2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

C Qi, J Gong, J Li, D Liu, Y Qin, S Ge, M Zhang… - Nature medicine, 2022 - nature.com
Despite success in hematologic malignancies, the treatment landscape of chimeric antigen
receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18. 2 (CLDN18. 2) …

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro …

X Zhang, H Liang, Z Li, Y Xue, Y Wang, Z Zhou… - The Lancet …, 2021 - thelancet.com
Background The optimal perioperative chemotherapeutic regimen for locally advanced
gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and …

[HTML][HTML] Appropriate PD-L1 cutoff value for gastric cancer immunotherapy: a systematic review and meta-analysis

T Xie, Z Zhang, X Zhang, C Qi, L Shen, Z Peng - Frontiers in oncology, 2021 - frontiersin.org
Background Immunotherapy dramatically changed the treatment landscape of gastric cancer
in recent years. PD-L1 expression was proposed as a biomarker; however, the treatment …

[HTML][HTML] Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives

Z Zhang, T Xie, X Zhang, C Qi, L Shen… - Chinese Journal of …, 2020 - ncbi.nlm.nih.gov
Despite the application of conventional therapies, the prognosis of advanced gastric cancer
(GC) or gastroesophageal junction cancer (GEJC) is still poor. In recent years, immune …

[HTML][HTML] Autophagy inhibition enhances PD-L1 expression in gastric cancer

X Wang, WKK Wu, J Gao, Z Li, B Dong, X Lin… - Journal of Experimental …, 2019 - Springer
Background Autophagy, a process for degrading intracellular substances to maintain basal
metabolic turnover, is known to be perturbed in gastric cancer. Programmed cell death-1 …

[HTML][HTML] Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid …

Y Xu, Y Wang, J Gong, X Zhang, Z Peng, X Sheng… - Gastric Cancer, 2021 - Springer
Purpose RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated
to MMAE via a cleavable linker. A phase I study was initiated to evaluate the toxicity, MTD …

[HTML][HTML] Early interdisciplinary supportive care in patients with previously untreated metastatic esophagogastric cancer: a phase III randomized controlled trial

Z Lu, Y Fang, C Liu, X Zhang, X Xin, Y He… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic
Esophagogastric Cancer: A Phase III Randomized Controlled Trial - PMC Back to Top Skip to …

[HTML][HTML] Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18. 2-positive gastric cancer

K Jia, Y Chen, Y Sun, Y Hu, L Jiao, J Ma, J Yuan, C Qi… - BMC medicine, 2022 - Springer
Background The FAST study identified claudin-18 (CLDN18. 2) as a promising novel
therapeutic target for gastric cancer (GC). However, the tumor immune microenvironment …

Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer

Y Hu, C Qi, X Liu, C Zhang, J Gao, Y Wu, J Yang… - Cancer Letters, 2019 - Elsevier
Peritoneal dissemination (PD) is the most frequent metastasis with poor prognosis in
patients with advanced gastric cancer (GC). However, the molecular mechanisms of PD …